Clinical Trial: NCT06198751
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Information Provided By: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Last Update Posted: | 2025-08-19 |
Study Overview
Brief Summary
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.
Official Title
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
Conditions
Breast Cancer
Intervention / Treatment
- Drug: 6.0 mg/kg of TQB2102 for injection
- Drug: 7.5 mg/kg of TQB2102 for injection
Other Study ID Numbers
- TQB2102-II-01
Start Date (Actual)
2024-02-05
Primary Completion Date (Actual)
2025-05-08
Study Completion Date (Estimated)
2028-02
Enrollment (Estimated)
104
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Information Provided By: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Last Update Posted: | 2025-08-19 |
Study Overview
Brief Summary
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.
Official Title
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
Conditions
Breast Cancer
Intervention / Treatment
- Drug: 6.0 mg/kg of TQB2102 for injection
- Drug: 7.5 mg/kg of TQB2102 for injection
Other Study ID Numbers
- TQB2102-II-01
Start Date (Actual)
2024-02-05
Primary Completion Date (Actual)
2025-05-08
Study Completion Date (Estimated)
2028-02
Enrollment (Estimated)
104
Study Type
Interventional
Phase
Phase 2